Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Next Previous
Trial Profile

EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Kidney-pancreas transplant rejection
  • Focus Therapeutic Use
  • Acronyms EMA-SPK

    • Most Recent Events

    • 23 Sep 2022 Primary endpoint (Occurrence of blindness) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Sep 2022 Primary endpoint (Worsening of visual acuity of more than 2 rows of Snellens optotypes) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
    • 23 Sep 2022 Primary endpoint (Newly diagnosed clinically significant macular edema) has been met, according to Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top